Brief: Almirall Says Phase 3B Adlong Clinical Study Show Treatment Outcomes With Up To Five Years Of Lebrikizumab

Almirall

01/10/2026 09:10

Oct 1 (Reuters) - Almirall, S.A. ALM.MC:
PHASE 3B ADLONG CLINICAL STUDY SHOW TREATMENT OUTCOMES OVER TIME WITH UP TO FIVE YEARS OF LEBRIKIZUMAB TREATMENT IN MODERATE-TO-SEVERE ATOPIC DERMATITIS
SUSTAINED EFFICACY AND SAFETY DEMONSTRATED BY 92.9% OF PATIENTS ACHIEVING EASI-75 AND 73.8% ACHIEVING EASI-90 AT END OF STUDY
AT WEEK 108 OF CONTINUOUS TREATMENT, 66.7% OF PATIENTS ACHIEVED CLEAR OR ALMOST-CLEAR SKIN
AT WEEK 108 OF CONTINUOUS TREATMENT, 78.0% REPORTED ABSOLUTE PRURITUS SCORE OF FOUR OR LESS ON THE PRURITUS NUMERICAL RATING SCALE
Source text
Further company coverage: ALM.MC

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))